NextPlat - Earnings Call - Q2 2025

Executive Summary

• Q2 revenue was $13.24M with diluted EPS of $(0.07); revenue declined versus both Q1 2025 ($14.53M) and Q2 2024 ($16.99M), driven by Healthcare softness, while e-Commerce continued to grow recurring airtime and saw improving hardware demand.
• Gross margin compressed to 21.8% (from 23.8% in Q1 and 34.5% YoY) on lower Healthcare prescription volume and 340B revenue and reimbursement pressure; OpEx fell to $4.71M as cost reductions took hold.
• Management flagged >$1M in anticipated annual expense savings and announced a Healthcare leadership expansion post-quarter to accelerate process improvements, 340B/LTC growth, and technology upgrades.
• No quantitative guidance was issued; management expects to be “active” on the share repurchase program in the coming quarter and is pursuing actions to regain Nasdaq compliance, while China tariff headwinds continue to delay Florida Sunshine (shift to UK/EU) and OPKO pet health products remain targeted for Q4 approval in China.

What Went Well and What Went Wrong

What Went Well

• e-Commerce momentum: “sale of satellite and connectivity products and services continues to see steady growth… record levels” of high-margin recurring airtime; hardware sales picked up with strength in IoT.
• Expense discipline: Operating expenses fell to ~$4.7M (from ~$4.9M in Q1 and ~$16.8M YoY) as stock comp rolled off and headcount/executive comp was reduced; annualized savings expected to exceed ~$1.0M.
• Loss narrowing YoY: Net loss attributable to common shareholders improved to $(1.789)M or $(0.07) per share vs $(5.311)M or $(0.28) YoY; cash ended the quarter at ~$16.6M.

What Went Wrong

• Healthcare contraction: Pharmacy Rx and other revenue fell to ~$8.2M (from ~$10.5M YoY), and 340B contract revenue fell to ~$1.0M (from ~$3.0M YoY) on relationship transitions, covered entities opening in-house pharmacies, and one ending 340B participation.
• Margin pressure: Consolidated gross margin slid to 21.8% (from 34.5% YoY); Healthcare margin fell to ~19.9% (from 35.2% YoY), with drug price inflation outpacing reimbursement adjustments.
• Tariff/regulatory friction: Florida Sunshine’s China launch is paused due to tariffs (shift to UK/EU); OPKO pet products still awaiting China regulatory approval (expected Q4; sales ~12 weeks post-approval).

Transcript

Speaker 0

Good day, ladies and gentlemen, and welcome to the NextPlat Corp second quarter 2025 earnings results conference call. At this time, all lines are in listen-only mode. Following the presentation, we will start a question-and-answer session. If at any time during this call you require immediate assistance, please press star here for the operator. This call is being recorded on Thursday, August 14, 2025. I will now like to return the conference over to management. Please go ahead.

Speaker 1

Good morning and welcome to NextPlat's second quarter 2025 earnings call. Thank you for joining us. Before I begin, I would like to acknowledge Charlie's passing in late May and again offer our condolences to his family. While we will briefly discuss the results of the second quarter, our objective today is to highlight many of the things we are doing now to build on the platform Charlie created. As we said at the end of June, our team has been very busy conducting a top-to-bottom review of the business. In particular, our healthcare operations that affect the majority of the business, and we believe has a large potential to contribute positively to NextPlat's growth and profitability. After I briefly recap the developments in the second quarter, Cecile Munnik, our CFO, will review our financial results and discuss activities in our healthcare segment.

We will conclude the call with a high-level discussion of our near-term objectives and developments, which we believe will positively drive the business forward. I will then conclude the conference call by responding to questions that were submitted by our shareholders. Trends from the first quarter have continued in regards to both challenges and positive progress in each of the businesses. In terms of e-commerce, here are some highlights. The sale of satellite and connectivity products and services continues to see steady growth in terms of both recurring high-margin airtime contracts, which are running at record levels, and a pickup in hardware sales, with particular strength in IoT product sales. Our sales of OPCO products in China continue to show steady product progress, primarily limited by our ability to import increasing levels of inventory as allowed by Tmall Global.

Nonetheless, we're still very excited about the prospects here, especially for pet products, a fast-growing market for which we hope to get regulatory approval in the fourth quarter of the year. Turning to Florida Sunshine, as you know, the tariff situation remains very volatile, and as such, while we are slowly advancing our efforts in the United States and in Europe, we continue to monitor the situation along with our Chinese partner, with a view to resuming launch plans there when conditions improve. In terms of healthcare, we are continuing to make positive progress in the face of several challenges, such as drug pricing and payer reimbursements. We are seeing the early positive impacts of cost reductions and operational efficiencies, with reductions in salaries and related costs and other general and administrative costs.

We are continuing to implement cost reduction and business process improvements, such as technology upgrades and the recruitment of dedicated sales professionals who are focused on opportunities in the 340B and long-term care segment. I will discuss some of the other things we are doing here after Cecile provides the financial highlights. At this point, I will turn the call over to Cecile to discuss our financial results for the three and six months ended June 30, 2025. Over to you, Cecile.

Speaker 2

Thank you, David. Good morning, everyone. I will now provide a summary of our results of operations for the three and six months ended June 30, 2025, and our financial and cash position as of June 30, 2025. Overall revenue for the second quarter of 2025 was approximately $13.2 million, compared to approximately $17 million in the same period last year. Our year-to-date overall revenue was approximately $27.8 million, compared to approximately $34.5 million for the same period last year. During 2025, the overall decrease in revenue was mainly due to the decline in our healthcare operations segment, which was partially offset by an increase in e-commerce operations revenue. The decrease in healthcare operations revenue for both the second quarter of 2025 and year-to-date period reflects a combination of factors.

First, the decrease in pharmacy prescription volume was influenced in part by the continued changes in provider relationships and shifts in patient flow due to the insurance network adjustments or provider decisions to align with different pharmacy partners. Second, we experienced changes in our 340B pharmacy service agreements where a couple of relationships transitioned to other pharmacy partners. Some covered entities opened in-house pharmacies, and another covered entity no longer participates in the 340B program. Our e-commerce operations experienced an increase in revenue for both the second quarter of 2025 and the year-to-date period, which was driven by growth in recurring airtime revenue, hardware sales, and favorable foreign currency impact.

Gross profits from our healthcare segment decreased to approximately 20% in the second half of 2025, from 35% in the second half of 2024, and was primarily attributable to the decrease in prescription volume and changes in 340B revenue, as well as the continued industry-wide impact of drug price increases outpacing reimbursement rate adjustments. Gross profits from our e-commerce segment decreased to approximately 26% in the second half of 2025, from 32% when compared to the same period of 2024, due to a service provider airtime contract that expired on December 31, 2024, which introduced new airtime costs beginning January 1, 2025, and temporary rate reductions for some customers affected by ongoing service interruptions.

As expected, overall operational costs decreased due to the elimination of several non-recurring expenses, such as impairment losses associated with goodwill and other intangible assets, and legal and consulting fees as it related to the merger of Progressive Care. We also experienced a reduction in salaries and wages. This was mainly a result of the decrease in stock-based compensation for non-recurring grants fully vested and a reduction in total headcount. During the second quarter, we remained focused on refining our expense structure. We are continuing to work towards achieving cost savings through initiatives such as optimizing our delivery process and renegotiating vendor contracts. Our commitment to driving cost reductions and improving overall operational efficiency remains steadfast as we move forward. We ended the second quarter with approximately $16.6 million in cash.

I encourage you to review our financial statements as contained in our quarterly report on Form 10-Q that was filed with the Securities and Exchange Commission. That concludes my remarks on financial results of the business. Back to you, David.

Speaker 1

Thank you, Cecile. At this point, I would like to highlight some of the near-term strategic developments we are working on, which we believe will positively impact the business over the next few weeks and months. As a result of our comprehensive business review, as outlined in our update letter, we have been very focused on our healthcare operations. This includes a review of our operations, processes, protocols, and staffing, all of which need to be properly aligned and funded if we are to deliver the results we are capable of. In the shorter term, our efforts include starting at the top and currently making personnel changes at managerial and supervisory levels to improve operating effectiveness and efficiency, with an emphasis on improving standard operating procedures that we expect will translate to cost savings.

Our new hires include Pharmacy Operations Managers with significant experience with long-term growth and strategic planning in community pharmacies in the South Florida region. We expect to announce developments on this very soon. Although we see continued progress in our 340B and long-term care business development efforts, with new contracts coming online during the quarter, we see opportunities for improvement here. This includes an increased focus on customer care, as well as the addition of dedicated sales and marketing professionals, some of which we have already hired, with others planned for later in the year. In fact, our initial hires have already attended two Florida healthcare conferences and identified sales prospects which they are pursuing. We are currently in late-stage negotiations and opening our first in-house pharmacy, further supporting a current 340B customer.

This represents a valuable new extension of our business, one we are looking to replicate with both new and existing customers. We hope to have more on this development in a few weeks. Finally, we are attempting to obtain specialty pharmacy accreditation, which will provide us with access to new sources of revenue derived from specialty pharmacy contracts with payers and healthcare providers. This could include expanding offerings for specialties in areas such as infusion therapies for the treatment of HIV to the delivery of chemotherapy. Developments here are expected during the fourth quarter. Now, before I respond to shareholder questions, I would like to make some closing remarks. After conducting our review, we are confident that there is value in our existing business, and there are opportunities for each of them which can support both growth and future value creation.

Our team and Board are aligned about the steps needed to proactively address the challenges we see, and importantly, the need to invest if we are to succeed over the longer term. As we stated previously, we are committed to transparency and to sharing with our investors the various steps we are taking as stewards of the company, and look forward to sharing our process with you each step of the way on our journey to push NextPlat forward. That concludes our formal remarks. We can now conduct the Q&A portion of today's call. We have again asked investors and shareholders to submit their questions in advance, and we would like to thank all of you who did. Question number one, what is the status of the buyback? Has the company repurchased any shares?

We have not yet repurchased any shares under our repurchase program, though we expect to be active in the coming quarter. We intend to be prudent in terms of deploying our variable cash for the repurchase of shares, as we do have other critical investments we intend to make, as outlined earlier on this call. Going forward, we only intend to provide updates regarding any repurchases on a quarterly basis. Question number two, the company is nearing the end of its initial 180-day minimum bid deficiency. What is the plan to regain compliance? We are monitoring the situation closely as we continue working to improve the financial results of the company. We believe our ability to execute and communicate the value of the strategic developments we outlined earlier and their positive contributions to our financial results will be central to how we address regaining compliance.

The other elements here include continued communication with investors and raising our profile within our industries, such as through new marketing campaigns and events, as you may have already seen from our Phillip Planco RX team. If we need to utilize the additional 180-day grace period afforded to us by NASDAQ, we will certainly pursue it. Question number three, given the uncertainties of doing business in China, should the company consider closing that part of the business if it isn't going to be able to generate the significant growth and profitability that the company anticipated? There are clearly tariff-related challenges for U.S.-made products like our Florida Sunshine, but for products like OPCO made internationally, the situation is different. Although progress with OPCO has been slower than we would like due to regulatory and inventory challenges, our early successes indicate a significant and potentially profitable opportunity.

Additionally, we plan to launch a range of OPCO animal health products as soon as regulatory approval is secured, enabling us to enter a high-growth market in China. Since we launched the sales of OPCO products in China, we have added valuable partners and in-market expertise, which gives us confidence in the long-term viability of this program. This combination of resources provides a platform that we can and will seek to continue to leverage as we move ahead. That was the final question that we received from investors. Thank you all again for submitting them. Please remember that you can submit your questions at our investor relations email, which is [email protected], or with our contact listed on our press releases, Michael Glickman, that's Mike at mwgco.net. That concludes our earnings conference call. We look forward to continuing to share with you our progress in the weeks and months ahead.

Have a nice rest of your day. Thank you.

Speaker 0

Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.

Speaker 1

Thank you.